Article Sidebar
Published:
Mar 12, 2019DOI:
10.4314/tjpr.v18i2.5Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Bryostatin inhibits proliferation of ependymoma cells by suppressing expressions of cyclooxygenase-2 and interleukin-8
Abstract
Purpose: To investigate the effect of bryostatin on the proliferation of ependymoma cells, and the underlying mechanism(s).
Methods: Ependymoma cell lines (SC-EPN1 and SC-EPN2) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal bovine serum (FBS) and streptomycin (10 mg/ml) in a humidified incubator at 37 °C and 5 % CO2 atmosphere. Rhe cells were randomly assigned to six groups: control group and five bryostatin groups treated with increasing concentrations of bryostatin (10 - 50 μM). Cell proliferation was determined by MTT assay, while real-time quantitative polymerase chain reaction (qRT-PCR) was used to determine the levels of expressions of apoptosisrelated genes. Expressions of cyclooxygenase-2 (COX-2), interleukin-8 (IL-8), Bcl-2, Bax and Pglycoprotein were determined using Western blotting.
Results: Treatment with bryostatin significantly and concentration-dependently down-regulated COX-2 and IL-8 mRNAs expressions (p < 0.05). On the other hand, proliferation of SC-EPN1 and SC-EPN2 cells were significantly and concentration-dependently inhibited by bryostatin, relative to control group (p < 0.05). After 72 h of treatment with bryostatin (50 μM), the extent of apoptosis was significantly higher in SC-EPN1 (57.43 %) and SC-EPN2 cells (52.29 %) than in control group (2.37 %, p < 0.05). The results of Western blotting showed that treatment with bryostatin significantly reduced the expressions of Bcl-2 in ependymoma cells, relative to the control group (p < 0.05). However, there were no significant differences in the expression of Bax among the groups (p > 0.05). P-glycoprotein expression was significantly higher in bryostatin groups than in control group (p < 0.05). The results of flow cytometric analysis of rhodamine-123 (rh123) fluorescence showed that after 72 h of treatment with bryostatin (50 μM), rhl23 fluorescence significantly decreased in SC-EPN1 (8.10 %) and SC-EPN2 cells (10.11 %), relative to control group (20.83 %, p < 0.05).
Conclusion: Bryostatin exerts anti-proliferative and apoptotic effects on ependymoma cells by suppressing COX-2 and IL-8 expressions. Thus, the inhibition of COX-2 expression may constitute an effective chemotherapeutic strategy for ependymoma treatment.
Keywords: Bryostatin, Ependymoma cells, Proliferation, Apoptosis, Expression
